KSL-128114 TFA

KSL-128114, a peptide inhibitor of the membrane regulator syntenin (Ki = 300 nM), notably diminishes the viability of A2058 melanoma and patient-derived glioblastoma multiforme (GBM) cells in a concentration-dependent manner. Furthermore, when administered at 50 μM, KSL-128114 elevates survival times in a patient-derived xenograft (PDX) mouse model of GBM, where mice were implanted intracranially with patient-derived GBM cells pre-cultured with KSL-128114.

OC(C(F)(F)F)=O.N=C(N)NCCC[C@@H](NC(C)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(NCC(N[C@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@@H](CO)C(N[C@@H](CC1=CN=CN1)C(N[C@H](C(N[C@@H](C(C)(C)C)C(N[C@@H](C2CCCCC2)C(N[C@@H](CC(O)=O)C(N[C@H](C(O)=O)[C@@H](C)CC)=O)=O)=O)=O)CC3=CNC4=CC=CC=C34)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O